| 6160.HK | BeOne Medicines Ltd Ordinary Shares | 8.92% |
| 1801.HK | Innovent Biologics Inc | 8.88% |
| 2269.HK | WuXi Biologics (Cayman) Inc | 7.58% |
| 603259.SS | Wuxi AppTec Co Ltd Class A | 5.84% |
| 600276.SS | Jiangsu Hengrui Pharmaceuticals Co Ltd Class A | 4.63% |
| 300760.SZ | Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A | 4.31% |
| 9926.HK | Akeso Inc Ordinary Shares | 3.75% |
| 1093.HK | CSPC Pharmaceutical Group Ltd | 3.71% |
| 1177.HK | Sino Biopharmaceutical Ltd | 3.41% |
| 02359 | Wuxi AppTec Co Ltd | 3.38% |
The fund will invest at least 80% of its net assets (plus borrowings for investment purposes) in instruments in its underlying index or in instruments that have economic characteristics similar to those in the underlying index. The underlying index is a free float adjusted market capitalization weighted index, subject to the 10/40 Constraint, which is designed to measure the equity market performance of Chinese companies in the healthcare sector. The fund is non-diversified.
KraneShares MSCI All China Health Care Index ETF · Issued by KraneShares
No recent news for KURE. The ingest cron pulls every 15 minutes during market hours.
See every ETF that holds KURE - directly and through fund-of-funds look-through - ranked by weight, with Pro reverse screening.
Upgrade to Pro